Orchard Therapeutics Reveals Enrollment of Initial Participant in Key Study of OTL-203 Targeting Hurler's Syndrome in MPS-I.

Rani Therapeutics Reports Encouraging Initial Outcomes from Phase 1 Trial of Oral RT-111, an Anti-IL-12/23 Antibody.

Johnson & Johnson has announced encouraging initial findings from a critical Phase 3 trial with nipocalimab for treating generalized myasthenia gravis, as well as from a Phase 2 investigation in Sjögren's Disease.

The Stage 2 trial for Technoderma's drug, TDM-105795, reveals positive outcomes for hair regeneration in individuals with pattern baldness.

Sangamo Therapeutics Reveals New Findings from Phase 1/2 STAAR Research for Fabry Disease Indicating Continuous Efficacy and Unique Safety Data.

Findings on CSL and Arcturus' sa-mRNA technology suggest extended immunity compared to standard mRNA COVID booster shots.

Incyte has declared the establishment of an asset acquisition deal with MorphoSys AG, granting Incyte unique worldwide privileges for the drug tafasitamab.

MorphoSys AG has officially declared that it has formed a strategic alliance through a Business Merger Contract with Novartis data42 AG and the principal entity, Novartis AG.

Henlius Confirms Phase 1 Pharmacokinetic Equivalence Trial of Denosumab HLX14 Achieves Positive Outcome.

Pliant Therapeutics Reports Positive Phase 2a INTEGRIS-PSC Trial Results for Bexotegrast in Primary Sclerosing Cholangitis with Suspected Liver Fibrosis.

Acepodia Reveals US Regulatory Approval for Pioneering Anti-EGFR Allogeneic Cell Treatment Trial, Designated as ACE2016.

Regeneron Pharmaceuticals, Inc. revealed that the European Medicines Agency is reviewing their Marketing Authorization Application for the therapy, linvoseltamab.